Redeye adds a new note to the previous analysis of Arocell on their website.
See full here: Redeye.se
Last week AroCell participated in three major events across the medical and research domains. From Paris to San Diego and Copenhagen, our team presented the latest advancements and interacted with industry and scientific leaders in the field. EAU Congress 2024 In...
A recent study investigated the use of urine-based biomarkers, including UBC Rapid, to monitor high-risk non-muscle invasive bladder cancer patients. The purpose of the study was to discover new applications for these biomarkers in order to safely reduce the frequency...
We are happy to announce that two abstracts on clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at the American Association of Cancer Research 2024 (AACR 2024) held from April 5 to 10 in San Diego, USA. One of the abstracts is...
